Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary SharesGlobeNewsWire • 02/09/21
Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis ImperfectaGlobeNewsWire • 12/17/20
Mereo BioPharma Provides Update on AIM Delisting and Continued Listing of its ADSs on Nasdaq, and Provides Update on agreements with Silicon Valley Bank and Kreos CapitalGlobeNewsWire • 12/15/20
Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical DevelopmentGlobeNewsWire • 11/23/20
Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory AffairsGlobeNewsWire • 10/20/20
Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)GlobeNewsWire • 10/19/20
Mereo BioPharma's (MREO) CEO Denise Scots-Knight on 2020 Interim Financial Results Conference Call TranscriptSeeking Alpha • 09/29/20
Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate UpdateGlobeNewsWire • 09/29/20
Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis ImperfectaGlobeNewsWire • 09/24/20
Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2020 and Host Conference Call on September 29, 2020GlobeNewsWire • 09/16/20
Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory DiseaseGlobeNewsWire • 08/25/20
Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and DevelopmentGlobeNewsWire • 06/30/20
Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019GlobeNewsWire • 06/16/20
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional InvestorGlobeNewsWire • 02/19/20
Mereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory ProgressGlobeNewsWire • 01/14/20
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for NavicixizumabGlobeNewsWire • 01/13/20